EA009376B1 - Нуклеиновые кислоты, специфично связывающие биоактивный грелин - Google Patents

Нуклеиновые кислоты, специфично связывающие биоактивный грелин Download PDF

Info

Publication number
EA009376B1
EA009376B1 EA200600735A EA200600735A EA009376B1 EA 009376 B1 EA009376 B1 EA 009376B1 EA 200600735 A EA200600735 A EA 200600735A EA 200600735 A EA200600735 A EA 200600735A EA 009376 B1 EA009376 B1 EA 009376B1
Authority
EA
Eurasian Patent Office
Prior art keywords
nucleic acid
ghrelin
nucleic acids
bioactive ghrelin
sziziz
Prior art date
Application number
EA200600735A
Other languages
English (en)
Russian (ru)
Other versions
EA200600735A1 (ru
Inventor
Свен КЛУССМАНН
Штеффен Хельмлинг
Дирк Эульберг
Кристиан Маш
Клаус БУХНЕР
Original Assignee
Нокссон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нокссон Фарма Аг filed Critical Нокссон Фарма Аг
Publication of EA200600735A1 publication Critical patent/EA200600735A1/ru
Publication of EA009376B1 publication Critical patent/EA009376B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
EA200600735A 2003-11-10 2004-11-10 Нуклеиновые кислоты, специфично связывающие биоактивный грелин EA009376B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03025743 2003-11-10
PCT/EP2004/012739 WO2005049828A1 (en) 2003-11-10 2004-11-10 Nucleic acids specifically binding bioactive ghrelin

Publications (2)

Publication Number Publication Date
EA200600735A1 EA200600735A1 (ru) 2006-10-27
EA009376B1 true EA009376B1 (ru) 2007-12-28

Family

ID=34610046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600735A EA009376B1 (ru) 2003-11-10 2004-11-10 Нуклеиновые кислоты, специфично связывающие биоактивный грелин

Country Status (19)

Country Link
US (2) US20070031840A1 (https=)
EP (1) EP1682662A1 (https=)
JP (1) JP4823067B2 (https=)
KR (1) KR20060125743A (https=)
CN (1) CN1894407A (https=)
AP (1) AP2006003618A0 (https=)
AU (1) AU2004291656A1 (https=)
BR (1) BRPI0415872A (https=)
CA (1) CA2544805A1 (https=)
CR (1) CR8388A (https=)
EA (1) EA009376B1 (https=)
EC (1) ECSP066559A (https=)
IL (1) IL175443A0 (https=)
MA (1) MA28153A1 (https=)
NO (1) NO20062663L (https=)
OA (1) OA13282A (https=)
TN (1) TNSN06132A1 (https=)
WO (1) WO2005049828A1 (https=)
ZA (1) ZA200603435B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750140B2 (en) * 2002-08-01 2010-07-06 Noxxon Pharma Ag Ghrelin binding nucleic acids
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
WO2008036765A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP2010510964A (ja) * 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
DK2104737T3 (da) * 2006-12-08 2013-05-27 Asuragen Inc Funktioner og formål for let-7 mikro-RNAer
WO2008073915A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en) * 2006-12-29 2008-07-17 Asuragen, Inc. Mir-16 regulated genes and pathways as targets for therapeutic intervention
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
JP2010529966A (ja) * 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてｍｉＲ−３４によって調節される遺伝子および経路
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20090186015A1 (en) * 2007-10-18 2009-07-23 Latham Gary J Micrornas differentially expressed in lung diseases and uses thereof
US8071562B2 (en) * 2007-12-01 2011-12-06 Mirna Therapeutics, Inc. MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
US20090263803A1 (en) * 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
EP2268832A2 (en) * 2008-03-06 2011-01-05 Asuragen, INC. Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
EP2493910A1 (en) 2009-10-30 2012-09-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
AU2012206750A1 (en) * 2011-01-10 2013-07-18 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
EP0786469B1 (en) * 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
JPH11505527A (ja) * 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
AU2001259056A1 (en) * 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
CA2411667A1 (en) * 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs
AR052741A1 (es) * 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013274A2 (en) * 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HELMLING STEFFEN ET AL.: "Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 36, 7 September 2004 (2004-09-07), pages 13174-13179, XP002321448, ISSN: 0027-8424, the whole document *
LEVA S. ET AL.: "GnRH binding RNA and DNA Spiegelmers: A novel approach toward GnRH antagonism", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 9, no. 3, March 2002 (2002-03), pages 351-359, XP002221140, ISSN: 1074-5521, the whole document *
RAGHAVAN M. ET AL.: "BIAcore: a microchip-based system for analyzing the formation of macromolecular complexes", STRUCTURE, CURRENT BIOLOGY LTD., PHILADELPHIA, PA, US, vol. 3, no. 4, April 1995 (1995-04), pages 331-333, XP004587855, ISSN: 0969-2126, the whole document *
WOOD S.J.: "DNA-DNA HYBRIDIZATION IN REAL TIME USING BIACORE", MICROCHEMICAL JOURNAL, NEW YORK, NY, US, vol. 47, no. 3, June 1993 (1993-06), pages 330-337, XP009004259, ISSN: 0026-265X, the whole document *

Also Published As

Publication number Publication date
AP2006003618A0 (en) 2006-06-30
JP4823067B2 (ja) 2011-11-24
KR20060125743A (ko) 2006-12-06
BRPI0415872A (pt) 2007-01-09
EP1682662A1 (en) 2006-07-26
AU2004291656A1 (en) 2005-06-02
WO2005049828A1 (en) 2005-06-02
CR8388A (es) 2006-10-17
ZA200603435B (en) 2007-06-27
JP2007513608A (ja) 2007-05-31
US20070031840A1 (en) 2007-02-08
CA2544805A1 (en) 2005-06-02
OA13282A (en) 2007-01-31
ECSP066559A (https=) 2006-11-24
TNSN06132A1 (fr) 2007-11-15
US20100261291A1 (en) 2010-10-14
NO20062663L (no) 2006-08-09
EA200600735A1 (ru) 2006-10-27
MA28153A1 (fr) 2006-09-01
CN1894407A (zh) 2007-01-10
IL175443A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
EA009376B1 (ru) Нуклеиновые кислоты, специфично связывающие биоактивный грелин
NL1031538C2 (nl) Ghrelinebindende nucleïnezuren.
AU2010243831B2 (en) Hepcidin binding nucleic acids
JP6514825B2 (ja) インスリン受容体アプタマーおよびこれを含む薬学的組成物
US10160973B2 (en) Nucleic acid aptamers binding to vascular endothelial growth factor receptors
JP4274831B2 (ja) シス・エレメントのデコイを用いる抗ガン剤
Yang et al. MicroRNA-155 inhibition attenuates myocardial infarction-induced connexin 43 degradation in cardiomyocytes by reducing pro-inflammatory macrophage activation
EP4400117A1 (en) Senolytic drug screening method and senolytic drug
Zhang et al. Cytokines increase CRE binding but decrease CRE‐mediated reporter activity in rat hepatocytes by increasing c‐Jun
KR20160062517A (ko) Ｄｐｐ­４ 저해제를 유효성분으로 함유하는 혈관 석회화 억제용 약학적 조성물
CN111991408B (zh) 槲皮素-3-o-刺槐糖苷作为钙离子通道的抑制剂的应用
JP5103187B2 (ja) バソプレッシン結合性のｌ体核酸
ES2368041T3 (es) Ácidos nucleicos de unión a ghrelina.
CN109096371B (zh) 一种降尿酸分子及其筛选方法和应用
EP1915170A1 (en) Use of neuropilin-2 antagonists
JP7082804B2 (ja) Ｒａｇｅアプタマーを含む癌を治療するための医薬組成物
CN112972485B (zh) 槲皮素-3′-O-β-D-葡萄糖苷作为钙离子通道的抑制剂的应用
KR20100000387A (ko) 뼈 형성 촉진 기능을 가지는 퍼모파민 유도체를 함유한조성물
HK1097879A (en) Nucleic acids specifically binding bioactive ghrelin
WO2007082053A2 (en) Trpm2-specific inhibitors
JP2004522449A (ja) 哺乳動物の中枢神経系におけるｔｏｂ遺伝子の機能と応用
CA3003576C (en) Dna aptamer that binds to vwf
Liu Development of ss DNA aptamers for c-Myc: Max by SELEX (Systematic Evolution of Ligands by Exponential Enrichment)
WO2003104454A1 (ja) 新規オキシダーゼ
WO2006052510A2 (en) Methods for identifying novel modulators of insulin signaling

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU